Wave Life Sciences Ltd
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent… Read more
Wave Life Sciences Ltd (WVE) - Total Assets
Latest total assets as of September 2025: $241.38 Million USD
Based on the latest financial reports, Wave Life Sciences Ltd (WVE) holds total assets worth $241.38 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Wave Life Sciences Ltd - Total Assets Trend (2013–2024)
This chart illustrates how Wave Life Sciences Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Wave Life Sciences Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Wave Life Sciences Ltd's total assets of $241.38 Million consist of 91.0% current assets and 9.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 85.8% |
| Accounts Receivable | $1.42 Million | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Wave Life Sciences Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Wave Life Sciences Ltd's current assets represent 91.0% of total assets in 2024, an increase from 33.5% in 2013.
- Cash Position: Cash and equivalents constituted 85.8% of total assets in 2024, up from 18.9% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 0.4% of total assets.
Wave Life Sciences Ltd Competitors by Total Assets
Key competitors of Wave Life Sciences Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Wave Life Sciences Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Wave Life Sciences Ltd generates 0.31x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Wave Life Sciences Ltd is currently not profitable relative to its asset base.
Wave Life Sciences Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.51 | 1.90 | 1.90 |
| Quick Ratio | 2.51 | 1.90 | 1.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $129.59 Million | $ 153.79 Million | $ 109.00 Million |
Wave Life Sciences Ltd - Advanced Valuation Insights
This section examines the relationship between Wave Life Sciences Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 20.40 |
| Latest Market Cap to Assets Ratio | 2.98 |
| Asset Growth Rate (YoY) | 28.1% |
| Total Assets | $352.21 Million |
| Market Capitalization | $1.05 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Wave Life Sciences Ltd's assets at a significant premium ( 2.98x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Wave Life Sciences Ltd's assets grew by 28.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Wave Life Sciences Ltd (2013–2024)
The table below shows the annual total assets of Wave Life Sciences Ltd from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $352.21 Million | +28.10% |
| 2023-12-31 | $274.95 Million | +87.82% |
| 2022-12-31 | $146.39 Million | -29.28% |
| 2021-12-31 | $207.01 Million | -25.87% |
| 2020-12-31 | $279.24 Million | -1.76% |
| 2019-12-31 | $284.25 Million | -3.95% |
| 2018-12-31 | $295.94 Million | +62.74% |
| 2017-12-31 | $181.84 Million | +10.33% |
| 2016-12-31 | $164.81 Million | -0.37% |
| 2015-12-31 | $165.42 Million | +5530.50% |
| 2014-12-31 | $2.94 Million | +26.47% |
| 2013-12-31 | $2.32 Million | -- |